<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35602875</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2376-0605</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Season>May-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>AACE clinical case reports</Title>
          <ISOAbbreviation>AACE Clin Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor-Interacting Protein-mutated Pediatric Somatotropinoma.</ArticleTitle>
        <Pagination>
          <StartPage>119</StartPage>
          <EndPage>123</EndPage>
          <MedlinePgn>119-123</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aace.2021.12.003</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Our objective was to describe the clinical course and treatment challenges in a very young patient with a pituitary adenoma due to a novel <i>aryl hydrocarbon receptor-interacting protein (AIP)</i> gene mutation, highlighting the limitations of somatostatin receptor immunohistochemistry to predict clinical responses to somatostatin analogs in acromegaly.</AbstractText>
          <AbstractText Label="CASE REPORT" NlmCategory="UNASSIGNED">We report the case of a 7-year-old boy presenting with headache, visual field defects, and accelerated growth following failure to thrive. The laboratory results showed high insulin-like growth factor I (IGF-I) (standardised deviation scores ( +3.49) and prolactin levels (0.5 nmol/L), and magnetic resonance imaging identified a pituitary macroadenoma. Tumoral/hormonal control could not be achieved despite 3 neurosurgical procedures, each time with apparent total resection or with lanreotide or pasireotide. IGF-I levels decreased with the GH receptor antagonist pegvisomant. The loss of somatostatin receptor 5 was observed between the second and third tumor resection. In vitro, no effect on tumoral GH release by pasireotide (with/without cabergoline) was observed. Genetic analysis revealed a novel germline <i>AIP</i> mutation: p.Tyr202∗ (pathogenic; class 4).</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">In vitro response of tumor tissue to somatostatin may better predict tumoral in vivo responses of somatostatin analogs than somatostatin receptor immunohistochemistry.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We identified a novel pathologic <i>AIP</i> mutation that was associated with incipient acrogigantism in an extremely young patient who had a complicated course of disease. Growth acceleration can be masked due to failure to thrive. Tumoral growth hormone release in vivo may be predicted with in vitro exposure to somatostatin receptor analogs, as it cannot be assumed that all <i>AIP</i>-mutated somatotropinomas respond well to pasireotide.</AbstractText>
          <CopyrightInformation>© 2021 AACE. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>van Santen</LastName>
            <ForeName>Selveta Sanne</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Endocrinology; Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daly</LastName>
            <ForeName>Adrian F</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Liège University Hospital Centre, Liège University, Avenue de L'hopital, Liège, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buchfelder</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery; University Hospital Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coras</LastName>
            <ForeName>Roland</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuropathology; University Hospital Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yining</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery; University Hospital Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beckers</LastName>
            <ForeName>Albert</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Liège University Hospital Centre, Liège University, Avenue de L'hopital, Liège, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van der Lely</LastName>
            <ForeName>Aart Jan</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Endocrinology; Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hofland</LastName>
            <ForeName>Leo J</ForeName>
            <Initials>LJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Endocrinology; Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balvers</LastName>
            <ForeName>Rutger K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery; Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Koetsveld</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Endocrinology; Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van den Heuvel-Eibrink</LastName>
            <ForeName>Marry Marrigje</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neggers</LastName>
            <ForeName>Sebastian Johannes Cornelis Martinus Maria</ForeName>
            <Initials>SJCMM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Endocrinology; Erasmus Medical Center, Rotterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>AACE Clin Case Rep</MedlineTA>
        <NlmUniqueID>101670593</NlmUniqueID>
        <ISSNLinking>2376-0605</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AIP mutation</Keyword>
        <Keyword MajorTopicYN="N">AIP, aryl hydrocarbon receptor–interacting protein</Keyword>
        <Keyword MajorTopicYN="N">GH, growth hormone</Keyword>
        <Keyword MajorTopicYN="N">IGF-I, insulin-like growth factor I</Keyword>
        <Keyword MajorTopicYN="N">LAR, long-acting release</Keyword>
        <Keyword MajorTopicYN="N">NR, normal range</Keyword>
        <Keyword MajorTopicYN="N">SDS, standardised deviation scores</Keyword>
        <Keyword MajorTopicYN="N">SSA, somatostatin analog</Keyword>
        <Keyword MajorTopicYN="N">SSTR, somatostatin receptor</Keyword>
        <Keyword MajorTopicYN="N">acromegaly</Keyword>
        <Keyword MajorTopicYN="N">gigantism</Keyword>
        <Keyword MajorTopicYN="N">macroadenoma</Keyword>
        <Keyword MajorTopicYN="N">pituitary adenoma</Keyword>
        <Keyword MajorTopicYN="N">somatotropinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>4</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35602875</ArticleId>
        <ArticleId IdType="pmc">PMC9123570</ArticleId>
        <ArticleId IdType="doi">10.1016/j.aace.2021.12.003</ArticleId>
        <ArticleId IdType="pii">S2376-0605(21)00127-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Daly A.F., Beckers A. The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am. 2020;49(3):347–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32741475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tichomirowa M.A., Barlier A., Daly A.F., et al.  High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165(4):509–515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21753072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vierimaa O., Georgitsi M., Lehtonen R., et al.  Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228–1230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16728643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Igreja S., Chahal H.S., King P., et al.  Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31(8):950–960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3065644</ArticleId>
            <ArticleId IdType="pubmed">20506337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oriola J., Lucas T., Halperin I., et al.  Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol. 2013;168(1):9–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23038625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadelha M.R., Kasuki L., Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013;24(5):238–246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23270713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daly A.F., Tichomirowa M.A., Petrossians P., et al.  Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373–E383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20685857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rostomyan L., Daly A.F., Petrossians P., et al.  Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22(5):745–757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533620</ArticleId>
            <ArticleId IdType="pubmed">26187128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi K., Daly A.F., Beckers A., Zacharin M. Resistant paediatric somatotropinomas due to AIP mutations: role of pegvisomant. Horm Res Paediatr. 2018;90(3):196–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29953972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidlingmaier M., Friedrich N., Emeny R.T., et al.  Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712–1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24606072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodoropoulou M., Tichomirowa M.A., Sievers C., et al.  Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer. 2009;125(9):2122–2126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19637311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freda P.U., Katznelson L., van der Lely A.J., Reyes C.M., Zhao S., Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–4473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15886238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Lely A.J., Hutson R.K., Trainer P.J., et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–1759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11734231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bevan J.S. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(3):1856–1863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15613435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruns C., Lewis I., Briner U., Meno-Tetang G., Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11980628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muhammad A., Coopmans E.C., Gatto F., et al.  Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab. 2019;104(3):915–924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30346538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hofland L.J., van der Hoek J., van Koetsveld P.M., et al.  The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89(4):1577–1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15070915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daly A.F., Rostomyan L., Betea D., et al.  AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect. 2019;8(4):367–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6454377</ArticleId>
            <ArticleId IdType="pubmed">30851160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogner E.M., Daly A.F., Gulde S., et al.  miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. Int J Cancer. 2020;147(12):3523–3538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32856736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coopmans E.C., Schneiders J.J., El-Sayed N., et al.  T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182(6):595–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32375119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iacovazzo D., Carlsen E., Lugli F., et al.  Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174(2):241–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26586796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korbonits M., Kumar A.V.  In: GeneReviews. Adam M.P., Ardinger H.H., Pagon R.A., et al., editors. University of Washington; 2012. AIP Familial isolated pituitary adenomas. Updated April 16, 2020. Accessed January 27, 2021.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
